MarketVIEW: Herpes Simplex Virus therapeutic (TX) vaccines (CAT No: VAMV038)

Published by: VacZine Analytics

Published: Jul. 1, 2012


Table of Contents

****This product is composed of a model and summary presentation
Contents – Summary presentation (MS PowerPoint based)
Author’s note
Executive Summary
Point(s) to note regarding vaccine pricing/usage
Commercial model – key model outputs
HSV TX vaccine: available market ($000s) to 2030 by scenario
HSV TX vaccine: demand (000s doses) to 2030 by scenario
HSV TX vaccine: available market ($000s) to 2030 (low scenario)
HSV TX vaccine: available market ($000s) to 2030 (base scenario)
HSV TX vaccine: available market ($000s) to 2030 (high scenario)
HSV TX vaccine: available market ($000s) to 2030 by country (base scenario)
HSV therapeutic vaccines: commercial model assumptions
Current management of genital herpes
The role of HSV TX vaccines
HSV TX vaccine target populations (scenario definition)
HSV TX vaccine: target product profile(s)
Model assumptions: populations/penetration rates/pricing/launch sequence
Markets included in model
Commercial model assumptions per TPP (LO/BASE/HI)
HSV TX vaccine segment analysis
Contribution of HSV-1 and HSV-2 to commercial value
HSV therapeutic vaccines: R&D pipeline
Competitor landscape: overview
HSV TX vaccine pipeline
Agenus
Preclinical programs
HSV therapeutic vaccines: Review on latest epidemiology
HSV-1/HSV-2: overview
HSV surveillance
Epidemiology: UK
Epidemiology: US
Epidemiology: other markets
HSV-1 and HSV-2 seroprevalence studies
Role of HSV-1 as a cause of genital herpes
Clinical reactivation of HSV-1 and HSV-2
Methodology: Calculating TX vaccine target populations
Bibliography
About VacZine Analytics
Disclaimer
Contents – Vaccine demand model (MS Excel-based)
Title sheet
Scenario definition
Chart – value
Chart – volume
Volume summary
Value summary (High price)
Value summary (Base price)
Value summary (Low price)
Country worksheets
US
Canada
UK
France
Spain
Italy
Germany
Other EU
Japan
Australia
Sources
Herpes database (UK)
Herpes database (US)
Diagnoses rates
US NDTI diagnoses
UK HPA diagnoses
UK HPA by age
US HSV-2 seroprevalence

Abstract

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although mostindividuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotionaland physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at thepublic health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylatic (PX) and therapeutic (TX) HSV vaccines albeit with littlesuccess to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need forlong-term pharmacotherapy. Ideally the vaccine would also reduce transmission so having a wider public health benefit.

This MarketVIEW1 product is a comprehensive MS Excel-based model + summary presentation which forecasts the potentialcommercial value of a therapeutic across the major Western markets to 2030. The model contains value ($ m) and volume (miodoses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI target product profile (TPP)scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included onlatest trends in disease epidemiology/dynamics.

Please note: this is delivered as a Zip file.

Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.